Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | Zendy

Antonio GonzálezMartín | Zendy; Bhavana Pothuri | Zendy; Ignace Vergote | Zendy; René dePont Christensen | Zendy; Whitney Graybill | Zendy; Mansoor R. Mirza | Zendy; Colleen McCormick | Zendy; Domenica Lorusso | Zendy; Paul Hoskins | Zendy; Gilles Freyer | Zendy; Klaus Baumann | Zendy; К. Jardon | Zendy; Andrés Redondo | Zendy; Richard G. Moore | Zendy; Christof Vulsteke | Zendy; Roisin E. O’Cearbhaill | Zendy; Bente Lund | Zendy; Floor Backes | Zendy; Pilar Barretina-Ginesta | Zendy; Ashley Haggerty | Zendy; María Jesús Rubio-Pérez | Zendy; Mark S. Shahin | Zendy; Giorgia Mangili | Zendy; William H. Bradley | Zendy; Ilan Bruchim | Zendy; Kaiming Sun | Zendy; Izabela A. Malinowska | Zendy; Yong Li | Zendy; Divya Gupta | Zendy; Bradley J. Monk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Author(s) -

Antonio GonzálezMartín,

Bhavana Pothuri,

Ignace Vergote,

René dePont Christensen,

Whitney Graybill,

Mansoor R. Mirza,

Colleen McCormick,

Domenica Lorusso,

Paul Hoskins,

Gilles Freyer,

Klaus Baumann,

К. Jardon,

Andrés Redondo,

Richard G. Moore,

Christof Vulsteke,

Roisin E. O’Cearbhaill,

Bente Lund,

Floor Backes,

Pilar Barretina-Ginesta,

Ashley Haggerty,

María Jesús Rubio-Pérez,

Mark S. Shahin,

Giorgia Mangili,

William H. Bradley,

Ilan Bruchim,

Kaiming Sun,

Izabela A. Malinowska,

Yong Li,

Divya Gupta,

Bradley J. Monk

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1910962

Subject(s) - medicine , ovarian cancer , chemotherapy , poly adp ribose polymerase , oncology , polymerase , brca mutation , cancer research , cancer , dna , biology , genetics

Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research